Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

  • 1Email author,
  • 1,
  • 2,
  • 3,
  • 4,
  • 1, 6 and
  • 5
BMC Psychiatry201414:313

https://doi.org/10.1186/s12888-014-0313-9

  • Received: 27 August 2014
  • Accepted: 27 August 2014
  • Published:

The original article was published in BMC Psychiatry 2013 13:20

Abstract

No abstract

Correction

After the publication of this work [1], we became aware that it contains inaccurate description. The correct description on page 5 was “At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups (p < .01) (Figure one)”, and not “At every timepoint, statistically significant differences were observed between IM olanzapine and IM placebo groups (p < .001) (Figure one).” We regret any inconvenience that this inaccuracy might have caused.

Notes

Authors’ Affiliations

(1)
Lilly Research Laboratories Japan, Eli Lilly Japan K.K, Kobe, Japan
(2)
Ayase Hospital, 6-3-1 Ayase, Adachi-ku, Tokyo 120-0005, Japan
(3)
Seishinkai Okehazama Hospital Fujita Kokoro Care Center, 3-879 Sakaecho Minamiyakata, Toyoake-shi 470-1168, Aichi, Japan
(4)
Numazu Chuo Hospital, 24-1 Nakasecho, Numazu-shi 410-0811, Shizuoka, Japan
(5)
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, 46285, IN, USA
(6)
Takahashi Psychiatric Clinic, Ashiya, Hyogo, Japan

References

  1. Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez JC: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatry. 2013, 13: 20-10.1186/1471-244X-13-20.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement